CORDIS - EU research results
CORDIS

Personalized And/Or Generalized Integrated Biomaterial Risk Assessment

Project description

Improving risk management in biomaterials

Biomaterials play a revolutionary role in modern medicine, as they are used in medical applications to support, enhance, or replace damaged tissue or biological functions. However, when biomaterials come into contact with the human body, unforeseen adverse reactions such as inflammation or infections often occur. The EU-funded PANBioRA project aims to develop a modular platform to assess these risks at different aspects and length scales. This platform encompasses antibody response, cytotoxicity/genotoxicity at the cellular level, as well as systemic and local effects at the tissue and organ-on-a-chip level. By enabling a time- and cost-effective risk assessment of new biomaterials in both healthy and disease states, this project aims to minimise side effects and enhance clinical outcomes, thereby reducing costs and time in healthcare.

Objective

PANBioRA aims at providing a comprehensive solution for the time- and cost-effective risk assessment of i) new biomaterials under health or disease states or ii) a given biomaterial for each patient in a personalized manner. It will standardize the evaluation of biomaterials and open the venue for pre-implantation, personalized diagnostics for biomaterial based applications.
PANBioRA will provide a modular platform to assess risks at different aspects and length scales. This comprises antibody response, cytotoxicity/genotoxicity at cell level, systemic and local effects at tissue and connected tissues (organ-on-a-chip) level. Moreover, physicochemical and biomechanical characterisation as well as predictive modelling at systems level will complement the system. This will be achieved by connecting testing modules in a structure supported by web-based modelling and risk radar tools together with a biomechanical testing system.
The platform will incorporate standardized protocols yielding significantly more information than the current methods for biomaterial risk assessment. Its accuracy will be demonstrated using known reference materials and validated in a pre-clinical setting.
PANBioRA will for the first time, predict the patient specific response to a given biomaterial before its implantation. This measure will allow for the selection of the best suitable material, minimizing side effects and improving health outcomes.
It will also accelerate the process of validation of the biocompatibility of new devices by providing an automated, comprehensive process for the parallel assessment of risks at different scales aiding new biomaterial discovery and commercialisation.
Altogether, PANBioRA will lead to a substantial economic impact due to a reduction of the amount of tests, decrease in healthcare costs due to complications. It will provide the necessary tools proper risk management related to biomaterials.

Call for proposal

H2020-NMBP-2016-2017

See other projects for this call

Sub call

H2020-NMBP-2017-two-stage

Coordinator

STEINBEIS 2I GMBH
Net EU contribution
€ 499 625,00
Address
LEUSCHNERSTRASSE 43
70176 Stuttgart
Germany

See on map

Region
Baden-Württemberg Stuttgart Stuttgart, Stadtkreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 499 625,00

Participants (19)